kabutan

Kringle Pharma, First Half Ordinary Profit Loss Widens, Jan-Mar Ordinary Profit Loss Widens

Mon May 12, 2025 3:40 pm JST Earnings

4884 Kringle Pharma,Inc. 【J-GAAP】

Earnings Report

Kringle Pharma,Inc. <4884> [TSE Growth] announced its financial results after the market closed on May 12th (15:40). The ordinary loss (non-consolidated) for the cumulative second quarter of the fiscal year ending September 2025 (October 2024 to March 2025) expanded to a loss of 511 million yen (compared to a loss of 365 million yen in the same period last year).

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the ordinary loss for the April to September period (2H) is expected to expand to a loss of 868 million yen (compared to a loss of 389 million yen in the same period last year).

In the most recent three-month period, from January to March (2Q), the ordinary loss expanded to a loss of 299 million yen (compared to a loss of 196 million yen in the same period last year). The operating profit/loss margin drastically worsened from -792.0% in the same period last year to -1758.8%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Oct - Mar, 2022 34 -314 -314 -315 -58.6 ー May 15, 2023 J-GAAP
Oct - Mar, 2023 43 -366 -365 -366 -60.2 ー May 13, 2024 J-GAAP
Oct - Mar, 2024 35 -511 -511 -512 -75.2 ー May 12, 2025 J-GAAP
YoY -18.6% -39.6% -40.0% -39.9% -24.8%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 Guidance ー ー ー ー － 0 Nov 13, 2024 J-GAAP
Oct - Mar, 2024 Results 35 -511 -511 -512 -75.2 0 May 12, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 37 -451 -389 -390 -61.0 0 Nov 13, 2024 J-GAAP
Apr - Sep, 2025 Guidance 237 -868 -868 -868 -124.0 0 May 12, 2025 J-GAAP
YoY +540.5% -92.5% -123.1% -122.6% -103.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Sep, 2023 69 -888 -852 -854 -158.5 0 Nov 13, 2023 J-GAAP
Sep, 2024 80 -817 -754 -756 -118.2 0 Nov 13, 2024 J-GAAP
Sep, 2025 Guidance 272 -1,379 -1,379 -1,380 -197.2 0 Nov 13, 2024 J-GAAP
YoY +240.0% -68.8% -82.9% -82.5% -66.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 25 -198 -196 -197 -32.4 -792.0 May 13, 2024 J-GAAP
Apr - Jun, 2024 18 -213 -152 -152 -24.3 -1,183.3 Aug 9, 2024 J-GAAP
Jul - Sep, 2024 19 -238 -237 -238 -37.2 -1,252.6 Nov 13, 2024 J-GAAP
Oct - Dec, 2024 18 -212 -212 -212 -31.2 -1,177.8 Feb 7, 2025 J-GAAP
Jan - Mar, 2025 17 -299 -299 -300 -44.0 -1,758.8 May 12, 2025 J-GAAP
YoY -32.0% -51.0% -52.6% -52.3% -35.9%

Related Articles